Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.55 |
| ▸ | FLT4 | P35916 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | WEE1 | P30291 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206145 | 0.91 | NTRK1 (0.49) | STK17ATNK2FLT4KDRNTRK1 | |
| SCHEMBL10207050 | 0.91 | TNK2 (0.54) | STK17ATNK2FLT4KDRWEE1 | |
| SCHEMBL10206174 | 0.90 | WEE1 (0.49) | STK17ATNK2FLT4KDRWEE1 | |
| SCHEMBL10206156 | 0.89 | ALK (0.48) | STK17ATNK2FLT4NTRK1PTK2 | |
| SCHEMBL10205882 | 0.89 | PTK2 (0.52) | FLT4KDRNTRK1PTK2 | |
| SCHEMBL10205156 | 0.88 | EGFR (0.47) | STK17ATNK2KDRNTRK1BTK | |
| SCHEMBL16255659 | 0.87 | EGFR (0.48) | STK17ATNK2FLT4KDRNTRK1 | |
| SCHEMBL10206633 | 0.87 | EGFR (0.46) | STK17ATNK2FLT4KDRWEE1 | |
| SCHEMBL10206144 | 0.87 | EGFR (0.59) | FLT4PTK2EGFRMET | |
| SCHEMBL10206600 | 0.86 | FLT4 (0.44) | STK17ATNK2FLT4KDRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | STK17A 3446/4885TNK2 646/4885FLT4 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.